Cargando…

Arterial function, biomarkers, carcinoid syndrome and carcinoid heart disease in patients with small intestinal neuroendocrine tumours

PURPOSE: Carcinoid heart disease (CHD) is a life-threatening complication of carcinoid syndrome (CS) characterised by tricuspid regurgitation (TR). However, there is an unmet need for earlier diagnosis of CHD. We cross-sectionally assessed the prevalence and potential predictive or diagnostic marker...

Descripción completa

Detalles Bibliográficos
Autores principales: Kostiainen, Iiro, Karppinen, Noora, Simonen, Piia, Rosengård-Bärlund, Milla, Lindén, Riikka, Tarkkanen, Maija, Gordin, Daniel, Rapola, Janne, Schalin-Jäntti, Camilla, Matikainen, Niina
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer US 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9242958/
https://www.ncbi.nlm.nih.gov/pubmed/35536452
http://dx.doi.org/10.1007/s12020-022-03065-0
_version_ 1784738183530938368
author Kostiainen, Iiro
Karppinen, Noora
Simonen, Piia
Rosengård-Bärlund, Milla
Lindén, Riikka
Tarkkanen, Maija
Gordin, Daniel
Rapola, Janne
Schalin-Jäntti, Camilla
Matikainen, Niina
author_facet Kostiainen, Iiro
Karppinen, Noora
Simonen, Piia
Rosengård-Bärlund, Milla
Lindén, Riikka
Tarkkanen, Maija
Gordin, Daniel
Rapola, Janne
Schalin-Jäntti, Camilla
Matikainen, Niina
author_sort Kostiainen, Iiro
collection PubMed
description PURPOSE: Carcinoid heart disease (CHD) is a life-threatening complication of carcinoid syndrome (CS) characterised by tricuspid regurgitation (TR). However, there is an unmet need for earlier diagnosis of CHD. We cross-sectionally assessed the prevalence and potential predictive or diagnostic markers for CS and CHD in a contemporary cohort of patients with small intestinal neuroendocrine tumours (SI-NETs). METHODS: Biochemical characteristics, hepatic tumour load, measures of arterial and endothelial function, atherosclerosis, and transthoracic echocardiography were analysed in a prospective cross-sectional setting. RESULTS: Among the 65 patients studied, 29 (45%) had CS (CS+ ), and 3 (5%) CHD. CS+ was characterised by significantly higher hepatic tumour load, S-5-HIAA and fP-CgA, higher frequency of diarrhoea and flushing, and more frequent PRRT compared to CS− (for all, P < 0.05). Central systolic, central mean, and central end-systolic blood pressures were significantly higher in CS+ than in CS− (for all, P < 0.05). Subjects with grades 2–4 TR had higher hepatic tumour burden, fP-CgA, and S-5-HIAA compared to those with grades 0–1 TR, but measures of vascular function did not differ. fP-CgA (P = 0.017) and S-5-HIAA (P = 0.019) but not proBNP increased significantly according to the severity of TR. CONCLUSION: Although CS is common, the prevalence of CHD was found to be lower in a contemporary cohort of SI-NET patients than previously anticipated. Measures of arterial or endothelial function or carotid atherosclerosis do not identify subjects with mild TR. Echocardiography remains the most sensitive means to diagnose CHD in CS patients with high tumour burden and elevated CgA and 5-HIAA.
format Online
Article
Text
id pubmed-9242958
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher Springer US
record_format MEDLINE/PubMed
spelling pubmed-92429582022-07-01 Arterial function, biomarkers, carcinoid syndrome and carcinoid heart disease in patients with small intestinal neuroendocrine tumours Kostiainen, Iiro Karppinen, Noora Simonen, Piia Rosengård-Bärlund, Milla Lindén, Riikka Tarkkanen, Maija Gordin, Daniel Rapola, Janne Schalin-Jäntti, Camilla Matikainen, Niina Endocrine Original Article PURPOSE: Carcinoid heart disease (CHD) is a life-threatening complication of carcinoid syndrome (CS) characterised by tricuspid regurgitation (TR). However, there is an unmet need for earlier diagnosis of CHD. We cross-sectionally assessed the prevalence and potential predictive or diagnostic markers for CS and CHD in a contemporary cohort of patients with small intestinal neuroendocrine tumours (SI-NETs). METHODS: Biochemical characteristics, hepatic tumour load, measures of arterial and endothelial function, atherosclerosis, and transthoracic echocardiography were analysed in a prospective cross-sectional setting. RESULTS: Among the 65 patients studied, 29 (45%) had CS (CS+ ), and 3 (5%) CHD. CS+ was characterised by significantly higher hepatic tumour load, S-5-HIAA and fP-CgA, higher frequency of diarrhoea and flushing, and more frequent PRRT compared to CS− (for all, P < 0.05). Central systolic, central mean, and central end-systolic blood pressures were significantly higher in CS+ than in CS− (for all, P < 0.05). Subjects with grades 2–4 TR had higher hepatic tumour burden, fP-CgA, and S-5-HIAA compared to those with grades 0–1 TR, but measures of vascular function did not differ. fP-CgA (P = 0.017) and S-5-HIAA (P = 0.019) but not proBNP increased significantly according to the severity of TR. CONCLUSION: Although CS is common, the prevalence of CHD was found to be lower in a contemporary cohort of SI-NET patients than previously anticipated. Measures of arterial or endothelial function or carotid atherosclerosis do not identify subjects with mild TR. Echocardiography remains the most sensitive means to diagnose CHD in CS patients with high tumour burden and elevated CgA and 5-HIAA. Springer US 2022-05-10 2022 /pmc/articles/PMC9242958/ /pubmed/35536452 http://dx.doi.org/10.1007/s12020-022-03065-0 Text en © The Author(s) 2022 https://creativecommons.org/licenses/by/4.0/Open Access This article is licensed under a Creative Commons Attribution 4.0 International License, which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The images or other third party material in this article are included in the article’s Creative Commons license, unless indicated otherwise in a credit line to the material. If material is not included in the article’s Creative Commons license and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain permission directly from the copyright holder. To view a copy of this license, visit http://creativecommons.org/licenses/by/4.0/ (https://creativecommons.org/licenses/by/4.0/) .
spellingShingle Original Article
Kostiainen, Iiro
Karppinen, Noora
Simonen, Piia
Rosengård-Bärlund, Milla
Lindén, Riikka
Tarkkanen, Maija
Gordin, Daniel
Rapola, Janne
Schalin-Jäntti, Camilla
Matikainen, Niina
Arterial function, biomarkers, carcinoid syndrome and carcinoid heart disease in patients with small intestinal neuroendocrine tumours
title Arterial function, biomarkers, carcinoid syndrome and carcinoid heart disease in patients with small intestinal neuroendocrine tumours
title_full Arterial function, biomarkers, carcinoid syndrome and carcinoid heart disease in patients with small intestinal neuroendocrine tumours
title_fullStr Arterial function, biomarkers, carcinoid syndrome and carcinoid heart disease in patients with small intestinal neuroendocrine tumours
title_full_unstemmed Arterial function, biomarkers, carcinoid syndrome and carcinoid heart disease in patients with small intestinal neuroendocrine tumours
title_short Arterial function, biomarkers, carcinoid syndrome and carcinoid heart disease in patients with small intestinal neuroendocrine tumours
title_sort arterial function, biomarkers, carcinoid syndrome and carcinoid heart disease in patients with small intestinal neuroendocrine tumours
topic Original Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9242958/
https://www.ncbi.nlm.nih.gov/pubmed/35536452
http://dx.doi.org/10.1007/s12020-022-03065-0
work_keys_str_mv AT kostiaineniiro arterialfunctionbiomarkerscarcinoidsyndromeandcarcinoidheartdiseaseinpatientswithsmallintestinalneuroendocrinetumours
AT karppinennoora arterialfunctionbiomarkerscarcinoidsyndromeandcarcinoidheartdiseaseinpatientswithsmallintestinalneuroendocrinetumours
AT simonenpiia arterialfunctionbiomarkerscarcinoidsyndromeandcarcinoidheartdiseaseinpatientswithsmallintestinalneuroendocrinetumours
AT rosengardbarlundmilla arterialfunctionbiomarkerscarcinoidsyndromeandcarcinoidheartdiseaseinpatientswithsmallintestinalneuroendocrinetumours
AT lindenriikka arterialfunctionbiomarkerscarcinoidsyndromeandcarcinoidheartdiseaseinpatientswithsmallintestinalneuroendocrinetumours
AT tarkkanenmaija arterialfunctionbiomarkerscarcinoidsyndromeandcarcinoidheartdiseaseinpatientswithsmallintestinalneuroendocrinetumours
AT gordindaniel arterialfunctionbiomarkerscarcinoidsyndromeandcarcinoidheartdiseaseinpatientswithsmallintestinalneuroendocrinetumours
AT rapolajanne arterialfunctionbiomarkerscarcinoidsyndromeandcarcinoidheartdiseaseinpatientswithsmallintestinalneuroendocrinetumours
AT schalinjantticamilla arterialfunctionbiomarkerscarcinoidsyndromeandcarcinoidheartdiseaseinpatientswithsmallintestinalneuroendocrinetumours
AT matikainenniina arterialfunctionbiomarkerscarcinoidsyndromeandcarcinoidheartdiseaseinpatientswithsmallintestinalneuroendocrinetumours